• SciSparc subsidiary NeuroThera Labs launched a U.S. Phase IIb trial site at Yale for SCI-110 in adult Tourette syndrome.
• SCI-110 combines dronabinol with palmitoylethanolamide in a single oral dose, targeting tic reduction with fewer side effects.
• Randomized, double-blind, placebo-controlled cross-over study tests efficacy at weeks 12 and 26 using the Yale Global Tic Severity Scale.
• Trial also runs at Hannover Medical School, Germany, and Tel Aviv Sourasky Medical Center, Israel.
• Phase IIa results showed a 21% average tic reduction on the Yale Global Tic Severity Scale Total Tic Score.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050822PRIMZONEFULLFEED9804184) on August 05, 2026, and is solely responsible for the information contained therein.